BeOne Medicines secured United States FDA approval for its blood cancer drug Beqalzi on Wednesday. The drug treats relapsed or refractory mantle cell lymphoma, an aggressive lymphatic system cancer. The approval expands Beqalzi's reach into a market with 3,300 new diagnoses annually.

FDA Grants Accelerated Approval for Beqalzi